Phase III trial (EORTC 18071 / CA184-029) of post-operative adjuvant ipilimumab compared to placebo in patients with resected stage III cutaneous melanoma: Health Related Quality of Life (HRQoL) results

INTRODUCTION: HRQoL was a secondary endpoint in the EORTC 18071 phase 3 trial in stage III melanoma patients comparing adjuvant Ipilimumab at 10 mg/kg (Ipi, N=475) versus placebo (Pbo, N=476). The primary endpoint was recurrence-free survival [HR (95% CI) = 0.75 (0.64–0.90); P=0.0013]. Toxicity of I...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Oncol
Main Authors: Coens, Corneel, Suciu, Stefan, Chiarion-Sileni, Vanna, Grob, Jean-Jacques, Dummer, Reinhard, Wolchok, Jedd D., Schmidt, Henrik, Hamid, Omid, Robert, Caroline, Ascierto, Paolo A., Richards, Jon M., Lebbe, Celeste, Ferraresi, Virginia, Smylie, Michael, Weber, Jeffrey S., Maio, Michele, Kotapati, Srividya, de Pril, Veerle, Testori, Alessandro, Eggermont, Alexander
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5636622/
https://ncbi.nlm.nih.gov/pubmed/28162999
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(17)30015-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados